Research programme: cancer immunotherapies - LIDDS

Drug Profile

Research programme: cancer immunotherapies - LIDDS

Alternative Names: NZ IO; NZ-Stimulator of Interferon Genes; NZ-STING

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LIDDS
  • Developer LIDDS; Uppsala University
  • Class Antibodies; Antineoplastics; Immunotherapies
  • Mechanism of Action Immunostimulants; MPYS-protein-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Jun 2018 LIDDS has patent protection for devices and methods for the reconstitution and administration of NanoZolid® formulations in North America, Asia and Europe
  • 15 Mar 2018 LIDDS has a patent pending for NZ STING
  • 23 Nov 2017 Preclinical trials in Cancer in Sweden (Intratumoural) before November 2017 (LIDDS pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top